Preparation method of p-aminobenzyl ertapenem sodium and its application in preparation research
By protecting the thiol group of the ertapenem side chain and condensing reaction under weak base conditions, combined with the reaction of MAP, the purity and yield of the aminobenzyl ertapenem sodium were successfully improved, and the structure of ertapenem sodium was solved. Poor stability and impurity generation problems have achieved high purity drug preparation.
Patent Information
- Application Number
- CN202111596551.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-24
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2041-12-24
AI Technical Summary
The poor structural stability of ertapenem sodium leads to the generation of impurities in the process of drug synthesis. The existing synthesis route has low yield and poor process stability, making it difficult to meet the requirements of drug quality control.
By protecting the sulfhydryl group of the ertapenem side chain, hydrotreating the p-nitrobenzyl ester is carried out, and the intermediate is synthesized with p-nitrobenzyl bromide under weak alkali conditions, then reacting with MAP and deprotection, and finally reducing Nitro is an amino group to produce p-aminobenzyl ertapenem sodium, and inorganic weak bicarbonate is used to react in acetonitrile at 50-55°C to improve the purity of the product.
The high purity preparation of aminobenzyl ertapenem sodium was achieved, with the product purity reaching 97%, which meets the quantitative and qualitative requirements of drug impurities research, the impurity content is <0.1%, and the process stability and yield are significantly improved.
Smart Images

Figure QLYQS_1 
Figure DEST_PATH_IMAGE002
Abstract
Description
Technical Field
[0001] The invention relates to a method for preparing carbapenem antibiotic impurities, and belongs to the field of pharmaceutical chemistry. Background Art
[0002] Ertapenem sodium was developed by Merck and launched in the United States and Europe in November 2001 and April 2002, respectively, and in China in 2005. Ertapenem sodium is a carbapenem antibiotic with the structural formula: It can be effectively used for moderate to severe infections caused by multidrug-resistant bacteria. It has strong antibacterial activity against cephalosporin-resistant ESBLs or AmpC and penicillin-resistant Streptococcus pneumoniae, and is considered an important line of defense against human infection. As the problem of bacterial resistance becomes more and more serious, people are paying more and more attention to carbapenem antibiotics.
[0003] Impurities are inevitably generated during the synthesis of drugs. Impurities in drugs pose certain safety risks to drug use. At present, the requirements for impurity research in the drug approval process are becoming increasingly higher at home and abroad. The 18 known impurities of ertapenem sodium are controlled in the United States Pharmacopoeia. The original research company Merck analyzed the main impurities in the preparation process in the literature (J.Org.Chem.2005,70,7479-7487), and specifically mentioned the production pathway of p-aminobenzyl ertapenem sodium: when intermediate A is hydrogenolyzed, intermediate compound I is produced, and further hydrogenation produces intermediate compound II, which is then converted into ertapenem sodium and compound III, and compound III is further converted into p-aminotoluene. The route is as follows. However, in this process, pyrrolidine in the structure of ertapenem sodium may react with compound III as a nucleophilic reagent, thereby producing the impurity p-aminobenzyl ertapenem sodium.
[0004]
[0005] p-Aminobenzyl ertapenem sodium is a known impurity O controlled in the US Pharmacopoeia ertapenem sodium variety, with a limit of <0.1%. Currently, there is no literature report on the synthesis of this compound.
[0006] Due to the structural characteristics of ertapenem sodium, it has poor stability and will be significantly degraded when stored at low temperatures. At the same time, since ertapenem sodium also contains two carboxyl groups in its structure, it is difficult to directly synthesize ertapenem sodium with p-aminobenzyl bromide. Therefore, the development of a stable and easy-to-operate synthetic preparation route for p-aminobenzyl ertapenem sodium is of great significance for the quality research and control of ertapenem sodium. Summary of the invention
[0007] Analysis of the structure of ertapenem sodium and the synthetic route reported in the literature show that it is mainly prepared by condensation reaction of MAP and ertapenem side chain, followed by hydrogenation and deprotection. The route is as follows:
[0008] .
[0009] The preparation of the side chain of ertapenem uses L-hydroxyproline as a raw material, which is first protected by p-nitrobenzyl ester, then converted into an active ester, thiolated, and aminolyzed. The route is as follows:
[0010] .
[0011] Based on the analysis of the side chain synthesis route, the inventors have tried to react sodium L-hydroxyproline with p-nitrobenzyl bromide and then apply the subsequent process of the side chain to synthesize the p-nitrobenzyl side chain. However, due to the change of the group and the extremely high water requirement for the preparation process of the active ester, the yield of the p-nitrobenzyl side chain obtained by this route is extremely low and the process stability is poor.
[0012] Therefore, the inventors developed a stable and easy-to-operate method for preparing p-aminobenzyl ertapenem sodium by further analyzing the side chain structure of ertapenem. The route is as follows:
[0013] .
[0014] First, the thiol group of the ertapenem side chain is protected by an acetyl group to obtain intermediate 1, and then the p-nitrobenzyl ester is removed by hydrogenation to obtain intermediate 2. Intermediate 2 is condensed with p-nitrobenzyl bromide under the action of a weak base to obtain intermediate 3. Intermediate 3 is deprotected from the acetyl group of the thiol group under the action of a base to obtain a p-nitrobenzyl side chain. The p-nitrobenzyl side chain reacts with MAP, and then hydrogenated and deprotected, and the nitro group is reduced to an amino group, so as to obtain the target compound p-aminobenzyl ertapenem sodium.
[0015] During the preparation process, if the thiol group of the side chain is not protected and the p-nitrobenzyl ester is directly removed before reacting with p-nitrobenzyl bromide, the product will contain a large amount of disubstituted products of the thiol group and pyrrolidine amine reacting with p-nitrobenzyl bromide simultaneously due to the strong reactivity of the thiol group.
[0016] The acid-binding agent in the reaction process of intermediate 2 and p-nitrobenzyl bromide is extremely important. When a strong base such as sodium hydroxide or potassium hydroxide is used, the acetyl protection of the thiol group will be destroyed, thereby producing a large amount of disubstituted products. Even if carbonate or an organic weak base is used, the reaction will produce a large amount of disubstituted products. Through a large number of experimental comparisons, the inventors found that the use of an inorganic weak base bicarbonate in acetonitrile at 50-55° C. has a better effect, and the product purity can reach more than 75%.
[0017] The route of the present invention is used to prepare p-aminobenzyl ertapenem sodium. Except for the slightly low yield of intermediate 3, the yields of other steps are all greater than 90%, the purity of the intermediates is all greater than 98%, and the purity of the target p-aminobenzyl ertapenem sodium is greater than 97%, which meets the quantitative and qualitative purity requirements in the study of drug impurities.
[0018] The p-aminobenzyl ertapenem sodium prepared by this process was used as an impurity reference substance and the ertapenem sodium freeze-dried powder injection prepared by different processes was tested using the external standard method. The results showed that the p-aminobenzyl ertapenem sodium was less than 0.1%. DETAILED DESCRIPTION
[0019] Example 1: Preparation of Intermediate 1
[0020] Add 60 g of ertapenem side chain, 16 ml of acetic anhydride and 200 ml of pyridine into a three-necked flask, stir and react at 15-20° C. for 4 hours, add 2000 ml of water, stir and crystallize for 1 hour, filter with suction, add 1000 ml of water to the filter cake and slurry it twice, filter with suction, and dry the filter cake at 40° C. to obtain 65.1 g of dry intermediate 1 with a yield of 99.3% and a purity of >99%.
[0021] Example 2: Preparation of Intermediate 2
[0022] 65.1g of intermediate 1, 325.5ml of purified water, 35.9g of sodium bicarbonate, 390.6ml of acetonitrile, and 52.1g of 5% palladium carbon (containing about 70% water) were added to an autoclave, kept at 20°C, and hydrogenated at a pressure of 1.2MPa for 8 hours. The material was discharged, filtered, and the filter cake was washed with water. The filtrate was adjusted to pH 5-6 with acetic acid, salt was added to saturation, 1400ml of ethyl acetate was added, stirred for 10 minutes, allowed to stand for 10 minutes, and filtered. It was noted that excess salt in the water should not be added to the suction funnel at this time. After the filter cake was drained, it was washed with ethyl acetate twice and dried at 40°C to obtain 37.6g of dry intermediate 2 with a yield of 91.3% and a purity of >99%.
[0023] Example 3: Preparation of Intermediate 3
[0024] 37.6 g of intermediate 2, 376 ml of acetonitrile, 30.8 g of sodium bicarbonate and 25.1 g of p-nitrobenzyl bromide were added to a three-necked flask, stirred at 50-55° C. for 12 hours, filtered, and the filtrate was concentrated to dryness under reduced pressure at 30° C. to obtain 46.9 g of an oily substance with a yield of 86.6% and a purity of 75.7%.
[0025] The oily substance was passed through a silica gel column and eluted with ethyl acetate-n-hexane 1:1. The column liquid of the target substance was collected and distilled under reduced pressure at 30°C to obtain 28.4 g of dry intermediate 3 with a purity of >98%.
[0026] Example 4: Preparation of Intermediate 4
[0027] Add 28.4 g of intermediate 3 to a 15-20°C sodium hydroxide aqueous solution (7.7 g + 568 ml), keep warm at 15-20°C with stirring for 1.5 hours, adjust the pH to 5-6 with acetic acid, stir and crystallize for 1 hour, filter with suction, wash with water, and dry at 40°C to obtain 23.7 g of dry intermediate 4, with a yield of 92.3% and a purity of >98%.
[0028] Example 5: Preparation of Intermediate 5
[0029] Add 35.1g MAP and 280.8ml DMF into a three-necked flask, cool to -5°C, add 23.7g intermediate 4, cool to -20°C, drop a mixture of 10.2g tetramethylguanidine and 70.2ml DMF, keep warm and react for 3 hours, add the reaction solution into 1000ml ice water, add acetic acid to adjust the pH to 5-6, stir and crystallize for 1 hour, filter with suction, wash with water to obtain intermediate 5 wet product with purity >98%.
[0030] Example 6: Preparation of p-aminobenzyl ertapenem sodium
[0031] The wet product of intermediate 5, 263 ml of purified water, 15.9 g of sodium bicarbonate, 351 ml of acetonitrile, and 44 g of 5% palladium carbon (containing about 70% water) were added to an autoclave, kept at 20°C, and hydrogenated at a pressure of 1.2 MPa for 3 hours. The product was discharged, filtered, and the filter cake was washed with water. The pH of the filtrate was adjusted to 5-6 with acetic acid, 3000 ml of isopropanol at 0-5°C was added, and the product was kept at 0-5°C for crystallization for 1 hour. The product was filtered, 150 ml of water was added to the wet product, and the product was freeze-dried to obtain 29.5 g of p-aminobenzyl ertapenem sodium. The total yield of the two steps from intermediate 4 to p-aminobenzyl ertapenem sodium was 82.9%, and the purity was >97%.
[0032] Example 7: According to the preparation scheme of Example 1 in patent CN100384845C, a lyophilized powder injection containing ertapenem sodium, sodium bicarbonate and sodium hydroxide was prepared, and the HPLC conditions of the relevant substances in the registration standard for imported drugs of the State Food and Drug Administration (standard number: JX20080052) were used for detection. At the same time, p-aminobenzyl ertapenem sodium prepared by the process described in this patent was used as an external standard. The impurity content of p-aminobenzyl ertapenem sodium in the lyophilized powder injection was less than 0.1%.
[0033] Example 8: According to the preparation scheme of Example 8 in patent CN103127097B, a freeze-dried powder injection of ertapenem sodium containing citric acid as a protective agent was prepared, and the HPLC conditions of the relevant substances in the registration standard for imported drugs of the State Food and Drug Administration (standard number: JX20080052) were used for detection. At the same time, p-aminobenzyl ertapenem sodium prepared by the process described in this patent was used as an external standard. The impurity content of p-aminobenzyl ertapenem sodium in the freeze-dried powder injection was less than 0.1%.
Claims
1. A method for preparing p-aminobenzyl ertapenem sodium, ; The steps include: (1) The thiol group of the side chain of ertapenem was protected by an acetyl group to obtain intermediate 1; (2) intermediate 1 is hydrogenated to remove p-nitrobenzyl ester to obtain intermediate 2; (3) Intermediate 2 is condensed with p-nitrobenzyl bromide in the presence of bicarbonate to give intermediate 3; (4) The acetyl protection of the thiol group of intermediate 3 is removed under the action of a base to obtain intermediate 4; (5) Intermediate 4 reacts with MAP to obtain intermediate 5; (6) The intermediate 5 is deprotected by hydrogenation and the nitro group is reduced to the amino group to prepare p-aminobenzyl ertapenem sodium.
2. The method for preparing p-aminobenzyl ertapenem sodium according to claim 1, Features: The acetylating agent used in the preparation of intermediate 1 is acetic anhydride.
3. The method for preparing p-aminobenzyl ertapenem sodium according to claim 1, Features: The solvent used in the preparation of intermediate 1 is pyridine.
4. The method for preparing p-aminobenzyl ertapenem sodium according to claim 1, Features: The solvents used in the preparation of intermediate 2 are aqueous sodium bicarbonate solution and acetonitrile.
5. The method for preparing p-aminobenzyl ertapenem sodium according to claim 1, Features: The bicarbonate used in the preparation of intermediate 3 is sodium bicarbonate or potassium bicarbonate.
6. The method for preparing p-aminobenzyl ertapenem sodium according to claim 1, Features: The solvent used in the preparation of intermediate 3 is acetonitrile.
7. The method for preparing p-aminobenzyl ertapenem sodium according to claim 1, Features: The reaction temperature in the preparation of intermediate 3 was 50-55°C.
8. The method for preparing p-aminobenzyl ertapenem sodium according to claim 1, Features: The base used in the preparation of intermediate 4 is sodium hydroxide or potassium hydroxide.
Citation Information
Patent Citations
Process for formulation of antibiotic compounds
CN100384845C
Ertapenem pharmaceutical compositions
CN103127097B
Ertapenem sodium freeze-dried preparation and preparation method thereof
CN103181904A
